Cardiology Medical News

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Pre-participation screening of young competitive athletes for prevention of sudden cardiac death

3. The Job Market for 2008-2009: Compensation

4. Renal Artery Stenosis

5. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Major adverse cardiac events at follow-up after bare-metal stenting versus drug-eluting stenting in ST-elevated myocardial infarction
The American Journal of Cardiology, 06/22/09

Pierre-Louis B et al. – Risk of developing major adverse cardiac events was 1.8 times greater for pts with bare-metal (BMS) vs drug-eluting stents (DES) after controlling confounding effects of previous coronary artery bypass surgery and stent width.

Methods

Percutaneous coronary intervention with stenting for 376 pts after thrombolytic therapy with tenecteplase for ST-segment elevation acute myocardial infarction

Results

Of 376 pts, BMS for 102 (27%); DES for 274 (73%) with sirolimus- or paclitaxel-eluting stents
At 43 mo of follow-up, major adverse cardiac events in 25 (25%) of 102 BMS pts vs 40 (15%) of 274 DES pts
On Cox regression analysis, significant independent prognostic factors for major adverse cardiac events: previous coronary artery bypass surgery, width of stent, and bare-metal stent

<< Previous
Is diabetes mellitus an independent risk factor for venous...

Next >>
Angiomodulin is a specific marker of vasculature and regulates...